cis-Dichlorodiammineplatinum(II) in non-small cell carcinoma of the lung

R. J. Gralla, E. Cvitkovic, R. B. Golbey

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


The role of cis-dichlorodiammineplatinum (II) (cis-platinum) as a single agent in non-small cell lung cancer has not been clearly defined, and extensive phase II studies have not been conducted. However, objective responses were noted in several early clinical trials. A review of these reports, including combinations with conventional agents, shows 15 partial responses among 100 patients. Results are presented on a new protocol using high-dose cis-platinum with mannitol-induced diuresis combined with cyclophosphamide and Adriamycin. An overall partial response rate of 28% was observed, including a 38% response rate in good performance status patients, with a median survival of 16 months in responding patients. Data from recent combination protocols do not define the activity of cis-platinum as a single agent, but suggest that it may be useful in non-small cell carcinoma of the lung.

Original languageEnglish (US)
Pages (from-to)1585-1588
Number of pages4
JournalCancer Treatment Reports
Issue number9-10
StatePublished - Dec 1 1979

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'cis-Dichlorodiammineplatinum(II) in non-small cell carcinoma of the lung'. Together they form a unique fingerprint.

Cite this